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Identification of genetic variations of influenza viruses
is essential for epidemic and pandemic outbreak surveil-
lance and determination of vaccine strain selection. In this
study, we combined a random amplification strategy with
high-density resequencing microarray technology to
demonstrate simultaneous detection and sequence-based
typing of 25 geographically distributed human influenza
virus strains collected in 2004 and 2005. In addition to iden-
tification, this method provided primary sequence informa-
tion, which suggested that distinct lineages of influenza
viruses co-circulated during the 2004–2005 season, and
simultaneously identified and typed all component strains
of the trivalent FluMist intranasal vaccine. The results
demonstrate a novel, timely, and unbiased method for the
molecular epidemiologic surveillance of influenza viruses.
I
nfluenza viruses are a major cause of respiratory infec-
tions in humans and result in substantial illness, death,
and economic problems throughout the world. Along with
regular seasonal epidemic outbreaks caused by common
circulating strains, novel strains emerge sporadically
because of reassortment in the segmented influenza RNA
genome and have resulted in devastating influenza pan-
demics (1–3). Since mutations and reassortments are often
determinants for infectious potential, antiviral drug sus-
ceptibility, and viral escape from vaccine-elicited immu-
nity, continually surveying the genetic composition (i.e.,
primary sequence) of circulating and emerging variants is
necessary. These needs have become increasingly relevant
recently because the World Health Organization (WHO)
has reported 85 human deaths caused by avian A/H5N1
influenza viruses throughout Asia since 2003 and raised
concerns about the potential for another influenza pan-
demic (4).
Automated Sanger/electrophoresis-based sequencing
technology has been used as the standard platform for
DNA and genome sequencing. Although conventional
sequencing produces accurate data, the requirement for
knowledge of template sequences and the inability to
quickly process multiple targets hinder its practical appli-
cation in epidemiologic and diagnostic investigations. As
an alterative, high-density oligonucleotide resequencing
microarrays represent a promising new technology that has
been used to rapidly and accurately identify nucleotide
sequence variants (5–7) from viral, bacterial, and eukary-
otic genomes (8–13). Use of resequencing microarrays to
detect single nucleotide polymorphisms and generate pri-
mary sequences enables identification of genetic variants
and provides valuable epidemiologic information that is
critical for outbreak surveillance. In most cases, however,
this technology has relied on specific amplification of a
limited number of target sequences before hybridization,
thus restricting throughput and limiting final identification
to strains that retain primer-targeted sequences. 
In an attempt to adapt resequencing microarray technol-
ogy to surveillance and diagnostics, we developed the res-
piratory pathogen microarray (RPM) version 1 for
detection and sequence typing of 20 common respiratory
and 6 category A biothreat pathogens known to cause
febrile respiratory illness (14). Alarge portion of RPM ver-
sion 1 is focused on a subset of tiled sequences correspon-
ding to partial fragments from the hemagglutinin (HA),
neuraminidase (NA), and matrix (M) genes for detection
of influenza Aand B viruses. In this study, we demonstrate
unbiased determination of viral subtype and lineage by
generation of primary sequence using random nucleic acid
amplification and resequencing microarray technology.
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RPM Version 1 Design
Each tiled prototype sequence was selected to have an
intermediate level of sequence homology across a group of
microbial or viral strains, which allowed for efficient
hybridization and unique identification of most or all sub-
types of targeted pathogenic species. For each relevant
base of a given prototype sequence, the array contains
eight 25mer probes (4 sense and 4 antisense). Two of 8
probes represent perfect matches, while the others corre-
spond to possible mismatches at the central (13th) position
of the 25mers. The prototype regions targeting influenza
viruses were composed of partial sequences from HA
genes of influenza A virus subtypes (H1, H3, and H5) and
influenza B virus, NA genes of influenza A virus subtypes
(N1 and N2) and influenza B virus, and the M genes of
influenza A virus (full-length M1 and partial M2) and
influenza B virus (Table 1). Both HA and NA regions
encompassed a sufficient number of polymorphic sites to
define subtypes. These regions were combined with proto-
type sequences for 22 other pathogens and tiled on 12.8-
µm chips (Affymetrix Inc., Santa Clara, CA, USA), which
contain ≈240 K 25mer probes and have the capacity to
resolve 30,000 nucleotides. The design and content of
RPM version 1 array have been previously described (14).
Sample Collection and Nucleic Acid Isolation
The influenza clinical specimens used in this study
were collected through the Department of Defense Global
Emerging Infections System during the 2004–2005
influenza season. Influenza throat swab specimens were
collected in accordance with the case criteria previously
described (15). Throat swabs were obtained within the first
72 h of the onset of symptoms, placed in viral transport
medium (MicroTest M4, Remel Inc., Lenexa, KS, USA),
and delivered by commercial carrier to the Air Force
Institute for Operational Health in Brooks City Base, San
Antonio, Texas, for culturing and molecular characteriza-
tion. Specimens were passaged once through primary rhe-
sus monkey kidney tissue culture (BioWhittaker,
Walkersville, MD, USA). Cultures were tested for influen-
za A or B viruses by using the centrifugation-enhanced
shell-vial technique with monoclonal antibody detection as
previously described (16). Cultures testing positive for
influenza A or B viruses were confirmed by using reverse
transcription–polymerase chain reaction (RT-PCR) analy-
sis with previously reported protocols (16,17). Total nucle-
ic acids were extracted from 90-µL cultured samples or
aliquots of live trivalent nasally administered influenza
vaccine (FluMist 2004/05, MedImmune, Inc., Gaithersburg,
MD, USA) by using the MasterPure DNA purification kit
(Epicentre Technologies, Madison, WI, USA) and dis-
solved in 30 µL of nuclease-free water. 
Random RT-PCR 
Total RNAamplification from cultured samples using a
random (RT-PCR) protocol was performed as previously
described (18) with minor modifications. Briefly, 4 µLo f
total nucleic acids were reverse transcribed with 40 pmol
of primer D (5′-GTTTCCCAGTAGGTCTCNNNN
NNNNN-3′) and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) in a 20-µL volume at
42°C for 1 h, followed by heat denaturation at 70°C for 15
min. Aliquots (10 µL) of the RT reaction products were
then amplified with the TaqPlus Long PCR System
(Stratagene, La Jolla, CA, USA) for 35 cycles in a 50-µL
volume consisting of 5 µL of 10× low salt buffer, 5 µL (25
mmol/L) MgCl2, 2 µL (10 mmol/L) dNTP mix, 1 µL
primer E (100 µmol/L) (5′-GTTTCCCAGTAGGTCTC-
3′), and 0.5 µL TaqPlus Long polymerase (5 U/µL). Each
cycle consisted of 94°C for 30 s, 40°C for 30 s, 50°C for
30 s, and 72°C for 2 min. This was followed by a final
extension at 72°C for 7 min. After amplification, the PCR
products were purified with the QIAquick PCR
Purification Kit (Qiagen, Valencia, CA, USA) and eluted
in 45 µL of EB buffer (10 mmol/L Tris, pH 8.5).
RPM Version 1 Hybridization and Processing 
Purified DNA amplicons were adjusted to 2 µg in 35
µL of EB buffer, mixed with 15.1 µL of fragmentation
cocktail buffer (5 µL NEB buffer 4, 5 µL 10 mmol/L Tris,
pH 7.8, and 0.1 µL GeneChip fragmentation reagent [3
U/µL], Affymetrix Inc.), and incubated for 10 min at 37°C
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biotin labeled with 1.5 µL of Biotin-N6-ddATP
(PerkinElmer Life and Analytical Sciences, Boston, MA,
USA) and 1 µL of terminal transferase (20 U/µL) (New
England Biolabs, Beverly, MA, USA) for 45 min at 37°C
and 15 min at 95°C. RPM version 1 arrays were prehy-
bridized with 200 µL of prehybridization buffer (10
mmol/L Tris, pH 7.8, and 0.01% Tween 20) for 15 min at
45°C. After the prehybridization step, 167.5 µLo f
hybridization cocktail master mix (3 mol/Ltetramethylam-
monium chloride, 10 mmol/L Tris, pH 7.8, 0.01% Tween
20, 0.5 mg/mL bovine serum albumin, 0.1 mg/mL herring
sperm DNA [Promega, Madison, WI, USA], 50 pmol/L
Oligo B2 [Affymetrix Inc.]) and biotin-labeled DNA frag-
ments were heated for 5 min at 95°C, equilibrated for 5
min at 45°C, and added to RPM version 1. All hybridiza-
tions were incubated for 16 h at 45°C in the GeneChip
hybridization oven 640 at 60 revolutions per minute. The
microarrays were then washed and stained with the
GeneChip Fluidics Station 450 and scanned with the
GeneChip Scanner 300 according to the GeneChip
CustomSeq array protocol. 
The hybridization intensities were analyzed with the
GeneChip operating software to generate raw image files
(.DAT) and simplified image files (.CEL) with intensities
assigned to each of the corresponding probe positions.
GeneChip DNA analysis software version 3.0 (GDAS),
which implements the ABACUS algorithm (7), was used
to produce an estimate of corrected base calls file (.CHP).
Base calls generated from each tiled region of the array
were then exported from GDAS as Federal Acquisition
Streamlining Act (FASTA)–formatted sequences.
DNA Sequencing
Automated DNA sequencing was performed as previ-
ously described (17). HAnucleotide sequences for influen-
za strains used in this study are available at GenBank
(accession nos. DQ265706–DG265730). The nucleotide
sequences of primers used for amplification and sequenc-
ing are available upon request. 
Sequence Analysis 
DNA sequences generated from RPM version 1 were
searched against the Influenza Sequence Database
(http://www.flu.lanl.gov/) (19) by using the BLAST algo-
rithm (20). Advanced options for blastn search were set as
follows: –W (word size) 7, –r (reward for a nucleotide
match) 1, –q (penalty for a nucleotide mismatch) –1. These
parameters were chosen to maximize sensitivity and allow
sequences with as many as 50% ambiguous calls to still
produce full-length searches. Sequence alignments were




To assess the performance of RPM version 1 with a
real-world clinical isolate set, we tested 25 cultured strains
collected from 4 continents during the 2004–2005 influen-
za season and previously diagnosed by culture and RT-
PCR as influenza. One influenza subtype was identified in
each tested sample based on the RPM version 1 hybridiza-
tion profiles and sequence reads shown in Figure 1A–C
and E. DNA fragments of HA1, NA1, and M genes ran-
domly amplified from an H1N1 isolate specifically
hybridized to their corresponding prototype regions on
RPM version 1 (Figure 1A). Prototype regions of 1
influenza subtype exhibited no interference from other
subtypes (Figure 1A–C), and prototype regions of other
pathogens on RPM version 1 showed no cross-hybridiza-
tion with any influenza virus segments (Figure 1D). Of the
25 isolates tested, we identified 12 A/H3N2, 12 influenza
B, and 1 A/H1N1 (Table 2). The A/H1N1 and A/H3N2
subtypes effectively hybridized to the same prototype M
sequence (derived from the A/NWS/33 H1N1 strain), con-
firming that M genes are conserved among different H/N
subtypes of influenza A to allow the universal identifica-
tion of influenza A subtypes with a single tiled prototype
region. A computational hybridization simulation model
we developed confirms this suggestion (A. Malanoski,
unpub. data). Aside from the highly conserved matrix
region, no cross-hybridization was observed between sub-
types, which suggests that the more variable HA and NA
tiles are subtype specific. The GDAS generated DNA
sequences from 3 genes (HA, NA, and M) from each sam-
ple with 42%–92% of the prototype tiled sequences, result-
ing in unambiguous calls by the microarray (Table 2). To
demonstrate the accuracy of microarray resequencing
reads, the HAgenes from all 25 samples were amplified by
a specifically primed RT-PCR and subjected to conven-
tional sequencing. The sequences produced by random
amplification and RPM version 1 were identical to those
identified by the conventional sequencing method with the
exception of ambiguous base calls (Ns). That is, in cases
where both methods assigned a base identity at a particu-
lar sequence position, those assignments were always
identical (data not shown). 
Sequence Analysis and Strain Identification
Microarray resequencing data and conventional
sequencing data were searched by using the Influenza
Sequence Database with the BLAST algorithm. Results for
the highest bit scores were taken as strain identifications
and are shown in Table 2. 
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Based on sequences of HA genes, which are routinely
used for genetic and antigenic characterization, microarray
strain identifications of all 13 influenza Aisolates correlat-
ed with identifications from the conventional sequencing
method. Although A/H3N2 isolates were sometimes
matched with different specific strain sequences from the
Influenza Sequence Database based on the top BLAST hits
for each isolate, all were redundant representatives of the
same A/Fujian/411/02 lineage identified by conventional
sequencing. These results indicate that ambiguous calls
(Ns) did not affect the accuracy of BLAST identification.
At most, only 6 mismatches occurred between the actual
sequence of each isolate and sequence of its top BLAST
search hit (Table 2, column M1).
Alignment of the HApeptide sequences translated from
RPM version 1–obtained DNA sequences for 12 A/H3N2
isolates (Figure 2) showed that they all shared signature
Fujian-like lineage amino acid substitutions (threonine and
histidine) at positions 155 and 156 (17). Serine (position
227), which is located within antibody binding site D, was
also conserved in these isolates, distinguishing them from
the A/California/7/04 strain, which has proline at this posi-
tion (17). In addition, isolate A/Ecuador/1968/04 shared
similar amino acids with those observed in the
A/Fujian/411/02 strain at antigenic sites A(lysine, position
145) and B (serine, position 189). Because of a more lim-
ited collection of NA and M gene sequences in the
Influenza Sequence Database, strain identifications based
on these 2 genes could only place them into clade Astrains
of H3N2 influenza A viruses sampled from New York
State, which caused the A/Fujian/411/2002-like epidemic
of the 2003–2004 influenza season (data not shown) (21).
Although the only tiled M sequence was adopted from an
A/H1N1 strain (A/NW/33), M results generated from the
H3N2 isolates were still clearly identifiable as belonging
to the A/H3N2 subtype and more specifically to the Fujian-
like strain. The A/England/400/05 isolate was the only iso-
late appropriately identified as A/H1N1, and all 3
sequences (HA, NA, and M) generated from RPM version
1 and conventional sequencing for this isolate matched
A/New York/227/2003 (H1N1). This is an A/New
Caledonia/20/99-like strain that has been consistently cir-
culating globally since 1999 (16).
Influenza B
The 12 influenza B isolates were classified as belong-
ing to 2 distinct subgroups based on BLAST searches of 3
genes generated from RPM version 1 analysis. The top
BLAST hits for the RPM-obtained sequences of the HA
gene identified subgroup 1 isolates as either
B/Milano/66/04 or B/Texas/3/2002, both of which are
B/Shanghai/361/2002-like strains and belong to the
B/Yamagata/16/88 lineage. BLAST queries of convention-
al sequencing data yielded similar identifications for these
isolates. Subgroup 2 isolates were identified as
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Figure 1. Hybridization images of the respiratory pathogen
microarray (RPM) version 1 prototype regions for 3 influenza virus
isolates and trivalent FluMist vaccine. A) A/H1N1, B) A/H3N2, C)
influenza B, and D) trivalent FluMist vaccine. In A, B, and C, only
the influenza-specific tiled prototype regions of RPM version 1 are
shown. Hybridization-positive identifications are shown on the
right. In D, the image of the entire RPM version when hybridized
with FluMist vaccine is shown. The single influenza prototype
region that was hybridization negative is denoted on the right. E)
Magnification of a portion of profile B showing an example of the
primary sequence data generated by the hybridization of random-
ly amplified targets to the RPM version 1 HA3 probe set. The pri-
mary sequence generated can be read from left to right. HA,
hemagglutinin; NA, neuraminidase; IQEX, internal positive
hybridization control (Affymetrix); M, matrix. B/Tehran/80/02 by microarray and as B/New York/1/2002
by conventional sequencing. The query results of both
methods were similar (different identification can be
attributed to ambiguous base calls), and all isolates were
members of the B/Victoria/2/87 lineage. This lineage is not
covered by the 2004–2005 influenza B vaccine (L. Daum,
pers. comm.). These results correspond to a Centers for
Disease Control and Prevention (Atlanta, GA, USA)
influenza activity report documenting that both of the iden-
tified influenza B lineages were reported worldwide and
that the Yamagata lineage viruses predominated in the
2004–2005 influenza season (22). 
Genotyping
RPM version 1 can differentiate a broad number of
variants based on a single-tiled “prototype” probe region
without relying on predetermined hybridization patterns
(9). Anumber of nucleotide mismatches that distinguished
tested isolates from tiled prototype probe sequences were
identified in each sample (Table 2, column M2). Some
were unique with respect to existing influenza database-
recorded sequences. All of these polymorphisms were ver-
ified by conventional sequencing (Table 3). Analysis of
HA sequences generated from 12 A/H3N2 isolates by
RPM version 1 showed that 4 of these nucleotide varia-
tions are common to 11 of the samples, excluding the out-
lying A/Ecuador/1968/04 isolate. Two of these common
base substitutions, 313 G→A and 352 A→C, are at the
third nucleotide of their respective codons and represent
synonymous mutations. Such mutations do not code for
amino acid changes and are usually selectively neutral and
much more likely to be shared by common ancestry than
by parallel evolution. These facts strongly support phylo-
genetic grouping of these 11 strains (Figure 3). In contrast,
393 A→T and 483 G→A are nonsynonymous mutations
and code for critical amino acid changes. Analysis of con-
ventional sequencing data confirmed that these 2 positions
are in the antigenic site B and that the affected amino acids
were changed from tyrosine to phenylalanine and from ser-
ine to asparagine, respectively. These 2 substitutions are
both characteristic features of the A/California/7/04 strain
that distinguish this group at both sequence and antigenic
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morphisms show that 11 of the 12 A/H3N2 isolates,
although collected from 4 continents, are members of the
same A/California/7/04 lineage, while the lone outlier,
A/Ecuador/1968/04, is clearly identified as a member of
the older A/Fujian/411/02 lineage. These observations
demonstrate that RPM version 1 data can be effectively
used for molecular epidemiologic tracking. 
Nearly every isolate was shown to have unique base
mutations, many of which resulted in amino acid substitu-
tions. Identification of these mutations reaffirms common
knowledge that genetic drift is a frequent event during cir-
culation of influenza viruses and that the RPM version 1
gene chip is an effective tool for tracking unique genetic
changes within influenza strains. 
Detection of Multiple Targets
To test the capability of RPM version 1 to detect multi-
ple pathogens with the random amplification protocol, we
analyzed total nucleic acid isolated from trivalent FluMist
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sequences on RPM version 1 were strongly hybridized by
randomly amplified FluMist nucleic acids, and the result-
ing sequence data confirmed that FluMist includes
immunogenic surface protein (HA and NA) genes from
influenza H1N1, H3N2, and influenza B strains. Sequence
analysis showed that these antigen-encoding genes
matched those of 3 wild-type influenza strains recom-
mended by WHO for making vaccine for the 2004–2005
season (Table 4). Two types of M genes from FluMist were
identified by RPM version 1 as those in the cold-adapted
Ann Arbor strains of influenza A and B, both of which are
essential components in the cold-adapted master donor
virus vaccine strain (23). 
Discussion
Because of the relative ease of transmission of respira-
tory pathogens, tremendous pressure exists to develop
rapid and sensitive tools to identify them. The surveillance
of influenza virus outbreaks requires identification not
only on the species level but also on the subtype or strain
level. Current molecular methods, such as PCR and multi-
plex PCR, have dramatically improved detection sensitiv-
ities and efficiency compared with culture and serologic
methods (24). However, they require multiple diagnostic
tests to discriminate between organisms at multiple phylo-
genetic levels and are inherently limited in scope and res-
olution (i.e., increases in resolution necessitate
corresponding decreases in scope). Furthermore, these
tests rely on the conservation of primer-targeted sequences
and as such can be rendered completely ineffective by as
little as a single base mutation.
Currently, most microarrays used for microbial detec-
tion are spotted arrays that use redundant oligonucleotides
as independent probes. For these methods, 2 types of probe
targets are usually considered. The first are conserved gene
sequences such as 16S rRNA and gyrase (25,26), which
are chosen for identification at the genus or family levels.
The second are relatively unique sequences such as viru-
lence factor genes and antigenic determinant genes
(27,28), which are used for species or serotype identifica-
tion. In this way, pathogen recognition by microarray
becomes as reliant on specific hybridization patterns as
PCR is on primer-target conservation. Thus, a microarray
is only able to resolve identity to the level of divergence
represented by the diversity of probes present on the array.
With resequencing arrays such as RPM version 1, multiple
contiguous sequences (range 100 bp to 2 kb) containing
both conserved and unique target genes from each species
or subtype can be selected as prototype regions, and every
nucleotide from the hybridized target regions can be poten-
tially read as an independent data point using resequencing
algorithms (5). The key advantage of the resequencing
array is that it does not require a specific match between
the analyzed sample and the probe, and mismatches actu-
ally add value because they can be identified and used as
strain-specific markers. 
Since the antigen-encoding HAand NAgenes are high-
ly variable between different subtypes, sequences specific
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Figure 2. Alignment of hemagglutinin
peptide sequences containing an influen-
za A/H3N2 prototype and the translated
sequences from 12 A/H3N2 isolates gen-
erated from respiratory pathogen
microarray version 1. A, antibody-binding
site; TH, antibody-binding site Fujian-like
lineage amino acid substitutions threo-
nine and histidine; B, antibody-binding
site; D, antibody-binding site. Asterisks
indicate conserved amino acids.
Figure 3. Unrooted phylogenetic analysis of the hemagglutinin 1
(HA1) gene of A) 11 influenza A/H3N2 isolates and B) 12 influen-
za B isolates compared with vaccine and reference strains. All clin-
ical isolates are available from GenBank under accession nos.
DQ265706-DG265730. *denotes the 2005–2006 influenza A/
H3N2 and influenza B vaccine strains.for HA1, HA3, HA5, NA1, and NA2 were all tiled on
RPM version 1 independently so that influenza A H3N2,
H1N1, and H5N1 viruses could be identified and rese-
quenced. Further analysis of the generated sequences
showed variations between target and prototype sequences
and accurately identified tested isolates at the strain level
and as members of recognized circulating variants (Table
2). With its capability to identify strains, the resequencing
microarray is a powerful tool for analysis of genetic char-
acteristics of circulating and emerging influenza viruses
and can be used to track movement of known variants.
Although only 1 type of M gene (H1N1), which is relative-
ly conserved among influenza Aviruses, was tiled on RPM
version 1, it was still able to cross-hybridize and differen-
tiate M genes from different subtypes (Figure 1 and Table
4). This tiled gene would theoretically allow detection of
any other type of influenza virus for which antigenic HA
and NA sequences were not tiled on the array. 
Another powerful feature of RPM version 1 is its
broad-spectrum detection capability, allowing simultane-
ous resequencing of dozens of gene targets from multiple
pathogens in 1 assay. This capability, however, is depend-
ent on an equally broad-spectrum amplification method.
With 66 diverse gene probes tiled on RPM version 1 cov-
ering 20 common respiratory and 6 biothreat pathogens
(14), it was logical to use a generic, sequence-independent
PCR strategy to amplify all potentially pathogen-derived
sequences in an unbiased fashion before hybridization. By
adopting a random amplification protocol (18) for use with
RPM version 1, we could simultaneously detect multiple
microorganisms, as shown with trivalent FluMist vaccine.
Correctly identifying 4 different influenza subtypes and
their corresponding genes provided a simultaneous
demonstration of 3 features of the resequencing microar-
ray: strain identification through pattern recognition,
sequence determination, and broad-spectrum capability.
Conventional sequencing can determine DNA sequence
and has been routinely used for genetic typing in surveil-
lance investigations (16,17,21,29). However, it requires
designing specific primers and multiple RT-PCRs to deter-
mine and amplify individual genes (such as HA, NA and
M) before proceeding with sequencing reactions (this is
especially true for highly polymorphic RNA viruses such
as influenza virus). This requires initial use of other lower
resolution techniques to identify strain type. All of these
steps are time-consuming and labor-intensive. RPM ver-
sion 1, combined with a random amplification protocol,
can provide sequence information about a wide variety of
genes representing many pathogens simultaneously and
rapidly without knowledge of the identity of the tested
sample. With the current possibility of an avian influenza
virus A/H5N1 pandemic (30), surveillance for and charac-
terization of emerging variants are essential to the rapid
implementation of control measures. 
In conclusion, we have combined a random amplifica-
tion strategy with a resequencing microarray to efficiently
and simultaneously detect, type, and genetically character-
ize geographically diverse influenza viruses. Application
of this and similar methods may aid in a better understand-
ing of the incidence, prevalence, and epidemiology of
influenza infections and simultaneously allow more rapid
identification of epidemic and pandemic outbreaks.  
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